Valeritas (NSDQ:VLRX) touted data today from an analysis showing that insulin-dependent people with Type 2 diabetes benefited from using the company’s wearable V-Go insulin delivery device.
The study featured people who previously treated their diabetes using multiple daily injections of insulin. After switching to the V-Go device under the care of advanced practitioners, participants were monitored and evaluated at the three- and seventh-month mark.
Get the full story at our sister site, Drug Delivery Business News.
The post Valeritas touts use of V-Go device compared to insulin injections appeared first on MassDevice.
from MassDevice https://ift.tt/2vtWmnO
Cap comentari:
Publica un comentari a l'entrada